2024
Improving Cefazolin Administration for Surgical Prophylaxis in Reported Penicillin Allergy: A Retrospective Study of a Health System Intervention
Belmont A, Son M, Hyman J, You L, Su C, Kashyap N, Topal J, McManus D, Martinello R, Kwah J. Improving Cefazolin Administration for Surgical Prophylaxis in Reported Penicillin Allergy: A Retrospective Study of a Health System Intervention. Journal Of Allergy And Clinical Immunology Global 2024, 100377. DOI: 10.1016/j.jacig.2024.100377.Peer-Reviewed Original ResearchPenicillin allergy labelHospital-wide guidelinesSurgical site infectionAllergy labelsSurgical patientsSevere allergic reactionsSurgical prophylaxisSite infectionAssociated with increased rates of surgical site infectionRate of surgical site infectionMulti-drug resistant infectionsAllergic reactionsPrevent surgical site infectionsFirst-line antibioticsFirst-line prophylaxisAdministration of cefazolinAssociated with increased ratesRetrospective cohort studyGuideline-directed therapyAdult surgical patientsPre-intervention groupPost-intervention groupPenicillin allergyPerioperative outcomesCefazolin administrationClinical manifestations and treatment outcomes for patients with Pseudomonas endocarditis
Shah S, Clarke L, Davis M, Topal J, Shields R. Clinical manifestations and treatment outcomes for patients with Pseudomonas endocarditis. Journal Of Antimicrobial Chemotherapy 2024, 79: 2017-2021. PMID: 38958234, DOI: 10.1093/jac/dkae205.Peer-Reviewed Original ResearchPseudomonas endocarditisFirst-lineClinical outcomesShorter time to treatment initiationFactors associated with treatment failureInvestigate clinical outcomes of patientsClinical outcomes of patientsTime to treatment initiationRate of adverse effectsProsthetic valve endocarditisFirst-line therapyOrgan transplant recipientsOutcomes of patientsInvestigate clinical outcomesIntracardiac complicationsDuke criteriaMicrobiological failureDrug discontinuationValve endocarditisCombination therapyTreatment failureTransplant recipientsDay mortalityInitial treatmentClinical benefitNocardiosis in Kidney Transplant Recipients and Possible Association With Decreased Utilization of Trimethoprim/Sulfamethoxazole During COVID-19
Marvin J, McSweeney T, Cohen E, Davis M, Belfield K, Do V, Virmani S, McManus D, Tirmizi S, Topal J. Nocardiosis in Kidney Transplant Recipients and Possible Association With Decreased Utilization of Trimethoprim/Sulfamethoxazole During COVID-19. Transplantation 2024, 108: e150-e151. PMID: 38917242, DOI: 10.1097/tp.0000000000004974.Peer-Reviewed Original ResearchClinical outcomes of baloxavir versus oseltamivir in immunocompromised patients
Ringer M, Malinis M, McManus D, Davis M, Shah S, Trubin P, Topal J, Azar M. Clinical outcomes of baloxavir versus oseltamivir in immunocompromised patients. Transplant Infectious Disease 2024, 26: e14249. PMID: 38319665, DOI: 10.1111/tid.14249.Peer-Reviewed Original ResearchLength of stayIntensive care unitBaloxavir groupClinical outcomesSecondary outcomesIntensive care unit length of stayRetrospective study of hospitalized patientsEfficacy of baloxavirResolution of feverImmunocompromised adult patientsStudy of hospitalized patientsRetrospective cohort studyAssociated with longer timeResolution of hypoxiaOseltamivir groupInfluenza subtypesImmunocompromised patientsInfluenza ANo significant differenceMedian timeResistance ratesNeuraminidase inhibitorsRetrospective studyBaseline characteristicsAdult patients
2023
2737. Real World Evaluation of Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant (aHSCT) Patients, Is Routine Antifungal Prophylaxis Needed?
Perreault S, Schiffer M, Roeder H, McManus D, Topal J. 2737. Real World Evaluation of Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant (aHSCT) Patients, Is Routine Antifungal Prophylaxis Needed? Open Forum Infectious Diseases 2023, 10: ofad500.2348. PMCID: PMC10678736, DOI: 10.1093/ofid/ofad500.2348.Peer-Reviewed Original ResearchInvasive fungal infectionsBreakthrough invasive fungal infectionsAntifungal prophylaxisFluconazole prophylaxisRisk factorsDay 75Conditioning regimenRisk patientsLower incidenceAllogeneic hematopoietic stem cell transplant patientsHistory of IFIRate of IFIHematopoietic stem cell transplant patientsHigh-intensity conditioning regimensStem cell transplant patientsFungal infectionsAnti-mold prophylaxisHigh-dose steroidsRoutine antifungal prophylaxisTacrolimus/sirolimusIntensity conditioning regimensHigh-risk patientsLow-risk patientsCell transplant patientsBreakthrough fungal infections